Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Millennium Pharmaceuticals, Inc.
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologic or cytologic diagnosis (recent or remote) of prostate adenocarcinoma
Radiographic evidence (recent or remote) of metastatic prostate adenocarcinoma
18 years of age or older
Progressive prostate cancer as defined by the presence of one or more of the following despite castrate levels of testosterone (testosterone \<50 ng/dL):
1. Progressive tumor lesions (changes in the size of lymph nodes or parenchymal masses on physical examination or X-ray and CT scan or MRI)
2. Progressive bone metastasis (presence of new lesion(s) on a bone scan)
3. Progressive PSA levels (as defined in Section 3.6.1)
Subjects who have received an anti-androgen must have shown progression of disease following discontinuation of the anti-androgen
Subjects must remain on luteinizing hormone-releasing hormone (LHRH) analog therapy for the duration of the trial unless surgically castrate
Agree to use an effective barrier method of contraception.
You may not be if
Testosterone \>50 ng/dL
Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of dosing
Use of PC-SPES within 4 weeks of dosing
Prior cytotoxic chemotherapy and/or radiation therapy within 6 weeks of dosing
Use of anti-androgen therapy (eg, flutamide, bicalutamide, nilutamide) within 6 weeks of dosing
Prior monoclonal antibody administration, including Prostascint®
Peripheral neuropathy of \> Grade 2, as defined by the NCI Common Toxicity Criteria for Adverse Events (NCI CTCAE)
History of CNS metastasis, including incompletely treated epidural disease
History of Hepatitis B or C
History of seizure disorder requiring active treatment and/or stroke
Serum creatinine \>2.0 mg/dL, or creatinine clearance \<60 mL/min if serum creatinine \>2.0 mg/dL
AST or ALT \>1.5 x ULN
Bilirubin (total) \>1.25 x ULN
Serum calcium \>12.5 mg/dL
Active serious infection not controlled by antibiotics
Active angina pectoris or NY Heart Association Class III-IV heart disease
Karnofsky Performance Status \<60%
Life expectancy \<6 months
Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems that might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.
